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ABSTRACT The Copenhagen Self-Sampling Initiative (CSi) has shown how human
papillomavirus (HPV)-based self-sampling can be used to increase screening partici-
pation among 23,632 nonattenders in the Capital Region of Denmark. In this study,
we describe HPV prevalence and genotype frequency in 4,824 self-samples as deter-
mined by three HPV assays (the CLART, Onclarity, and Hybrid Capture 2 [HC2] as-
says) and compare the results with those for physician-taken follow-up samples. The
HPV self-sample ﬁndings were also compared to the ﬁndings for a reference popula-
tion of 3,347 routinely screened women from the Horizon study, which had been
undertaken in the same screening laboratory. Nonattenders had an HPV prevalence
of 11.3% as determined by the CLART assay, which was lower than that for women
from the Horizon study (18.5%). One-third of the CSi women who tested HPV posi-
tive by self-sampling tested HPV negative on the physician-taken follow-up sample.
The CLART and Onclarity assays agreed on 64% (95% conﬁdence interval [CI], 60 to
68%) of the HPV-positive self-taken samples. When the HC2 assay results were added
into a three-way comparison, the level of agreement decreased to 27% (95% CI, 24 to
29%). Our ﬁndings suggest that further validation of HPV assays on self-taken samples is
needed for optimal HPV detection and correct clinical management of HPV-positive
women.
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Human papillomavirus (HPV)-based self-taken samples can be an alternative tocervical cytology screening for women who do not attend screening (nonattend-
ers) (1, 2). A meta-analysis showed that with speciﬁc combinations of collection devices
and HPV assays, the accuracy of detection of high-grade cervical intraepithelial neo-
plasia (CIN2) was similar to that with physician-based sampling (3). Most self-
sampling studies to date have used the Hybrid Capture 2 (HC2) assay for HPV testing
(2, 4–11), but currently, no single HPV assay is recognized as the gold standard. On
routine screening with physician-taken samples, assays are considered validated if they
show noninferiority to the HC2 assay or GP5/6 PCR, the two assays that were the
basis for four European randomized trials (12). However, no guideline exists on the
criteria for the use of HPV assays with self-taken samples.
The pilot implementation of “The Copenhagen Self-Sampling Initiative” (CSi) was
initiated to investigate whether self-sampling by nonattenders was a viable option for
increasing participation in screening. Another aim was to compare three HPV assays on
self-taken samples. By use of an opt-in strategy, 20% of 23,632 invited nonattenders
returned self-taken samples (13). All samples were tested in a split-sample protocol with
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the CLART HPV2 (Genomica, Madrid, Spain) and BD Onclarity HPV (BD, Sparks, MD, USA)
tests. Moreover, a limited subset of 1,008 samples was also tested using the HC2 assay
(Qiagen, Hilden, Germany), which was the routine assay in the laboratory at the time
the pilot started. Women with a positive result on any of the HPV assays were
recommended to have a physician take a cytology sample, to be cotested for cytology
and HPV, as follow-up.
The frequencies of different HPV genotypes among self-sampling nonattenders are
infrequently reported in the literature, mainly because the majority of the studies used
the HC2 assay, which does not allow one to distinguish between the HPV genotypes
detected. In this study, we not only employed assays with extended or full genotyping
but also compared the ﬁndings to those of the Danish Horizon study, a previous study
using physician-taken samples from routinely screened women, where the CLART assay
was also used in that study.
One of the major outcomes of the Horizon study was that the frequencies of CIN2
detection were fairly similar for the assays compared, but the assays detected different
HPV infections in the same samples (14). On samples from approximately 3,000 women
undergoing primary screening, only 27% of all infections detected by four commercially
available assays were conﬁrmed by all assays, and when the assays were compared
pairwise, only half of all HPV infections were conﬁrmed on both assays. No similar HPV
assay performance issues on self-taken samples have been described earlier.
In this study, we compared the detection of HPV infections by three assays (CLART,
Onclarity, and HC2) and the subsequent cytology results for women with detected
infections. The ﬁndings were compared to those for routine screening samples from the
Horizon study (15, 16).
RESULTS
High-risk HPV (HR-HPV) infections were detected in 769 (15.9%) self-taken samples,
based on a positive test result on any assay (where testing by the HC2 assay was
undertaken only on the ﬁrst 1,008 samples). The Onclarity assay showed the highest
prevalence (14.1%), followed by the CLART and HC2 assays (11.3% and 7.2%, respec-
tively) (Table 1). The HPV prevalence detected in self-taken samples appeared to be
lower than that for physician-taken samples in the Horizon study (18.5%) when tested
by the CLART assay. This was also the case with the age-speciﬁc prevalences. The
prevalence of HPV appeared not to be related to the women’s screening history. Of the
769 women who tested positive for HPV, 641 went for follow-up (follow-up compliance
rates were 83% for all ages, 90% at the ages of 27 to 29 years, 82% at 30 to 39 years,
84% at 40 to 49 years, 77% at 50 to 59 years, and 87% at 60 to 65 years [data not
tabulated]). Almost one-third of the women with physician-taken follow-up samples
after a positive self-taken sample had a diagnosis of atypical squamous cells of
undetermined signiﬁcance or higher-grade lesions (ASCUS), a proportion 2-fold
higher than that for women in the Horizon study with a positive HPV test at baseline.
HPV16 was the genotype most frequently observed both for routinely screened
women and in self-sampling, constituting 25.4% and 24.3%, respectively, of the HR-HPV
types (data not tabulated), and with a detected prevalence of 2.9% in self-sampling. The
second most frequent HR-HPV genotype in self-sampling was HPV51 (2.0%), followed
by HPV31 (1.6%) (Table 2). In the Horizon study, the most frequent genotypes were
HPV16 (4.5%), HPV31 (2.8%), and HPV52 (3.2%). Infections with more than one HPV
genotype were observed in approximately 56% of all HPV-positive samples in the
Horizon study, whereas for self-sampling, the prevalence of multiple infections was
below 48% (data not tabulated). The numbers and proportions of women with high-
and low-risk infections are shown in Table 3.
Of 736 HR-HPV infections detected by the Onclarity or CLART assay in the CSi study,
a total of 471 infections (64% [95% conﬁdence interval {CI}, 60 to 68%]) were detected
by both assays (Table 4; Fig. 1A). Women for whom infections were detected by both
assays were more likely to have a diagnosis of ASCUS.
The relatively low agreement was not substantially increased when genotype HPV66
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was included on the CLART assay so that it would match the genotypes targeted by the
Onclarity assay. The levels of agreement were highest for HPV16, HPV31, and HPV52 (all
75%), whereas the lowest level of agreement was observed for HPV45 (40%) (Table 4).
When the HC2 assay was added into the comparison, with 964 valid test results, the
TABLE 1 Prevalence of high-risk HPV in 4,824 self-taken samples from the CSi pilot, as detected by the Onclarity, CLART, and HC2 assays,
by age, screening history, and subsequent cytology test results for HPV-positive women, compared with results for 3,347 women
undergoing primary cytological screening in the Horizon study
Characteristic
No. (%) of self-taken primary screening samples in the CSia
No. (%) of physician-taken
primary screening samples
in the Horizon studyOnclarity and CLART HC2
Total tested
HPV positive
by Onclarity
HPV positive
by CLART Total tested
HPV
positive Total tested
HPV positive
by CLART
Age group (yr)
27–29 383 (100.0) 98 (25.6) 82 (21.4) 63 (100.0) 15 (23.8) 478 (100.0) 165 (34.5)
30–39 1,080 (100.0) 205 (19.0) 170 (15.7) 201 (100.0) 19 (9.5) 1,295 (100.0) 273 (21.1)
40–49 1,200 (100.0) 142 (11.8) 124 (10.3) 255 (100.0) 22 (8.6) 897 (100.0) 116 (12.9)
50–59 1,265 (100.0) 138 (10.9) 105 (8.3) 279 (100.0) 11 (3.9) 462 (100.0) 45 (9.7)
60–65 896 (100.0) 97 (10.8) 63 (7.0) 210 (100.0) 6 (2.9) 215 (100.0) 19 (8.8)
Total 4,824 (100.0) 680 (14.1) 544 (11.3) 1,008 (100.0) 73 (7.2) 3,347 (100.0) 618 (18.5)
Screening historyb for women
aged 34 yr
Long-term unscreened 1,599 (100.0) 190 (11.9) 147 (9.2) 337 (100.0) 19 (5.6) 133 (100.0) 20 (15.0)
Intermittently screened 2,416 (100.0) 287 (11.9) 229 (9.5) 525 (100.0) 28 (5.3) 2,158 (100.0) 287 (13.3)
Total 4,015 (100.0) 477 (11.9) 376 (9.4) 815 (100.0) 47 (5.8) 2,291 (100.0) 307 (13.4)
Physician-taken cytology samples
from HPV-positive women
Normal 457 (71.3) 384 (68.8) 318 (66.9) 50 (73.5) 509 (82.4)
ASCUS 182 (28.4) 172 (30.8) 156 (32.8) 18 (26.5) 109 (17.6)
Inadequate 2 (0.3) 2 (0.4) 1 (0.2) 0 (0.0) 0 (0.0)
Total 641 (100.0) 558 (100.0) 475 (100.0) 68 (100.0) 618 (100.0)
aCSi, Copenhagen Self-Sampling Initiative; HC2, Hybrid Capture 2 assay. Invalid test rates were 3.9% (n  191) and 0.5% (n  23) for the Onclarity and CLART assays,
respectively. By deﬁnition, the HC2 assay reports no invalid test results. Three samples (0.1%) were inadequate for HPV testing by both the CLART and Onclarity
assays. Because HPV results were required to be reported to women within 10 days of the arrival of the sample in the laboratory, women received their results based
on the CLART and HC2 assays only for the 191 samples that were invalid by Onclarity.
bLong-term unscreened, no cytology sample registered in the Patobank in 10 years; intermittently screened, one or more cytology samples registered within the
past 10 years.
TABLE 2 Distribution of high-risk HPV genotypes among women undergoing self-
sampling in the CSi study, compared with that for routinely screened women
participating in the Horizon study, by use of the CLART assay
High-risk HPV genotype
Total no. (prevalence [%]) of infectionsa in the
following study:
CSib (n  4,801) Horizonc (n  3,336)
HPV16 138 (2.9) 150 (4.5)
HPV18 29 (0.6) 57 (1.7)
HPV31 76 (1.6) 95 (2.8)
HPV33 30 (0.6) 67 (2.0)
HPV35 46 (1.0) 42 (1.3)
HPV39 18 (0.4) 20 (0.6)
HPV45 23 (0.5) 39 (1.2)
HPV51 97 (2.0) 79 (2.4)
HPV52 74 (1.5) 107 (3.2)
HPV56 19 (0.4) 35 (1.0)
HPV58 52 (1.1) 91 (2.7)
HPV59 42 (0.9) 49 (1.5)
HPV68 5 (0.1) 55 (1.6)
aThe numbers of infections with the different genotypes do not add up to the total numbers of women with
high-risk HPV infections (544 in the CSi study and 618 in the Horizon study) because some women had
multiple HPV infections.
bSamples from 4,824 women were tested by the CLART assay. Of these, 4,801 (99.5%) had valid results.
cSamples from 3,347 women were tested by the CLART assay, and 3,336 (99.7%) had valid results.
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level of positive agreement was 27% (Fig. 1B). In pairwise comparisons, the level of
agreement between the CLART and HC2 assays was 38%, and that between the
Onclarity and HC2 assays was 33%. The detected prevalence of HPV infections in this
subset was similar to that in the entire study (14.8% by the Onclarity assay, 10.0% by
the CLART assay, 7.4% by the HC2 assay, and 17.2% by any of the three assays).
Almost two-thirds of women with HPV-positive test results were also found HPV
positive in the follow-up sample (69.1% for the CLART assay and 63.7% for the Onclarity
assay) (Table 5). Women who came early for follow-up had a slightly lower HPV
prevalence on the follow-up sample than women who came later, although the
difference was not statistically signiﬁcant (P  0.67) (data not reported).
The use of the cycle threshold (CT) values of the internal controls included in the
Onclarity assay, as well as the CT values for positive samples, allowed a quantitative
evaluation of sample quality. Mean CT values on self-taken samples were approximately
2 cycles lower than those on physician-taken samples for all three human beta-globin
(HBB) control wells (mean differences, 2.00 with HBB1, 1.99 with HBB2, and 1.99
with HBB3), indicating a larger concentration by volume of human material in self-taken
samples than in physician-taken samples (Table 6). Discrepant sample sets with HPV-
positive self-taken samples but HPV-negative physician-taken samples showed higher
genotype-speciﬁc CT values on the self-taken sample than did the concordant sample
sets (by 2 to 5 cycles) (Table 7). Concordant sample sets tended to have similar
TABLE 3 Numbers and proportions of women with high- and low-risk HPV infections in
the CSi and Horizon studies
Patient group
No. (%) of women with infections
detected in the following study:
CSi Horizon
Total with high-risk HPV infections 544 (11.3) 618 (18.5)
A single high-risk HPV infection 284 (5.9) 272 (8.2)
Multiple infections, including 1 high-risk
HPV genotype
260 (5.4) 346 (10.4)
Total with low-risk HPV infectionsa 618 (12.9) 375 (11.2)
aThe CLART assay detected 1 or more of the 22 low-risk genotypes but no high-risk HPV infection.
TABLE 4 Agreement between the CLART and Onclarity assays on self-taken samplesa
Type of infection
Total no. (%)
positive by:
Total no. of
infections
No. of samples:
% positive
agreement
(95% CI)Onclarity CLART
Positive by
both assays
Positive by CLART,
negative by
Onclarity
Negative by CLART,
positive by
Onclarity
By deﬁnition of a positive
CLART test resultb
1 of 13 high-risk genotypes 680 (14.7) 527 (11.4) 736 471 56 209 64.0 (60.4–67.5)
1 of 13 high-risk genotypes
or HPV66
680 (14.7) 573 (12.4) 748 505 68 175 67.5 (64.0–70.9)
By genotypec
HPV16 149 (3.2) 135 (2.9) 162 122 13 27 75.3 (67.9–81.7)
HPV18 46 (1.0) 28 (0.6) 47 27 1 19 57.4 (42.1–71.7)
HPV31 89 (1.9) 76 (1.6) 94 71 5 18 75.5 (65.6–83.8)
HPV45 58 (1.3) 23 (0.5) 58 23 0 35 39.7 (27.0–53.3)
HPV51 73 (1.6) 93 (2.0) 100 66 27 7 66.0 (55.8–75.2)
HPV52 72 (1.6) 70 (1.5) 81 61 9 11 75.3 (64.5–84.2)
aOf 4,824 samples, 4,612 (95%) had valid HPV results on both assays.
bFor management purposes, and in line with the latest IARC deﬁnitions, we assumed that the CLART assay detected high-risk HPV infections if it detected one or
more of the 13 high-risk genotypes (HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68). According to the manufacturer’s settings, the Onclarity assay
returns a positive result if 1 or more of the 13 high-risk genotypes or HPV66 is detected (14 genotypes in total).
cComparison of genotype agreement was possible only with 6 HPV types, because the Onclarity assay reports the remaining 8 targeted genotypes (HPV33, -58, -35,
-39, -68, -59, -39, and -66) in combination.
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genotype-speciﬁc signal strengths. Finally, CT values tended to be lower in self-taken
samples found positive by all three HPV assays than in self-taken samples that were
positive only by the Onclarity assay (difference in median signal strengths, about 8
cycles) (Table 8).
DISCUSSION
General ﬁndings. Among self-sampling attenders, the prevalence of HR-HPV was
between 11% (by the CLART assay) and 14% (by the Onclarity assay), and about
one-third of HPV-positive women had abnormal cytology upon follow-up. Agreement
in the detection of HR-HPV between the CLART and Onclarity assays was observed in
approximately two-thirds of cases overall, and in three-fourths of cases when HPV16,
HPV31, or HPV52 infections were involved. About one-third of the women whose
FIG 1 Agreement of the HC2, Onclarity, and CLART assays on the detection of HPV in self-taken samples and cytology diagnoses from follow-up samples. Note
that ASCUS was determined on physician-taken follow-up samples by cytology, and the different denominators reﬂect the completeness of follow-up in each
subgroup. (A) In total, 4,612 samples gave valid results on the Onclarity and CLART assays. Of these samples, 736 (16.0%) were positive by at least one of the
two assays, and 609 (81%) of the women with positive results had a follow-up cytology registered. (B) In total, 964 samples gave valid results on all three assays
(HC2, Onclarity, and CLART). Of these, 166 (17.2%) were positive by at least one of the assays, and 150 of the women with positive results (90.4%) had a follow-up
cytology registered.
TABLE 5 High-risk HPV prevalence agreement between self-taken samples and physician-taken follow-up samples stratiﬁed by follow-up
timea
Test and follow-up time
for self-taken samples
No. of physician-taken
follow-up samples
received
No. of physician-taken samples
positive for high-risk HPV by
the same assay
High-risk HPV prevalence agreement (%)
between self-taken samples and
physician-taken follow-up samples (95% CI)
CLARTb
27 days 279 188 67.4 (61.5–72.9)
27 days 174 125 71.8 (64.5–78.4)
Total, all samples 453 313 69.1 (64.6–73.3)
Onclarityc
27 days 326 196 60.1 (55.8–64.3)
27 days 206 133 64.6 (54.6–71.1)
Total, all samples 532 339 63.7 (59.7–68.0)
aThe follow-up time was the number of days between the date on which the HPV result on the self-taken sample was sent to the woman and the date on which the
follow-up cytology sample was registered in the Patobank. The median follow-up time was 27 days.
bThe CLART assay detected high-risk HPV infections in 544 of 4,824 self-taken samples (11.3%). Of these, 453 (83.3%) had a valid HPV test result on the physician-
taken follow-up sample.
cThe Onclarity assay detected high-risk HPV infections in 680 of 4,824 self-taken samples (14.1%). Of these, 532 (78.2%) had a valid HPV test result on the physician-
taken follow-up sample.
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self-taken samples tested HPV positive were found to be HPV negative on the
physician-taken follow-up sample, and this was particularly the case when the signal
strength in the self-taken sample was close to the manufacturer-set cutoff, indicating
small amounts of viral input material. The detected HR-HPV prevalences, overall and
genotype speciﬁc, were lower than those in a routinely screened population from the
same uptake area, although among the infected women, the proportion with abnormal
cytology was higher.
Strength and limitations. Both the CSi and the Horizon study were population-
based studies undertaken in a routine screening laboratory. Our laboratory is the sole
provider of cervical screening for this part of Denmark; it has a long-standing cervical
screening program with a 75% coverage rate (17). Hence, our ﬁndings are represen-
tative for the general population in a real-world setting, even though the laboratory’s
catchment area during the Horizon study included only the urban Copenhagen and
Frederiksberg municipalities, whereas during the CSi study, the catchment area had
been expanded to include the periurban areas of the entire Capital Region (including
the former Copenhagen, Frederiksborg, and Bornholm counties besides the two mu-
nicipalities). Moreover, the same senior laboratory staff participated in the two studies,
ensuring the same standards for both studies. Finally, since our laboratory is the
principal site for the validation of the Onclarity assay on SurePath samples (18), we have
several years of experience in operating the Onclarity assay and instrumentation.
A limitation of the comparisons between the HC2, Onclarity, and CLART assays in the
CSi may be that BD’s Cervical Brush Diluent (CBD) medium, which was used to
TABLE 6 Comparison of CT values for human beta-globin by the Onclarity assay on self-
taken and physician-taken follow-up samplesa
HBB typeb
(no. of valid results)
CT (95% CI)
Mean differencec
(95% CI)Self-taken samples
Physician-taken
follow-up samples
HBB1 (496) 21.85 (21.68–22.02) 23.85 (23.71–23.98) 2.00 (2.19, 1.83)
HBB2 (500) 21.83 (21. 67–22.00) 23.83 (23.69–23.97) 1.99 (2.17, 1.81)
HBB3 (498) 21.65 (21.49–21.81) 23.66 (23.53–23.79) 1.99 (2.17, 1.82)
aOf the 4,824 women with a self-taken sample, 680 tested HPV positive by the Onclarity assay. Of these, 504
(74.1%) women had a follow-up sample with a valid result. CT, cycle threshold.
bHBB, human beta-globin. Onclarity has three controls, in three different bulks, for human beta-globin
material (HBB1, HBB2, and HBB3). For eight women, the CT value was reported as zero for either the self-
taken sample or the follow-up sample with HBB1, but valid CT values were returned with HBB2 and HBB3,
leaving 496 pairs of valid CT values for the analysis. Four samples with HBB2 and six samples with HBB3
failed to yield valid results.
cCalculated by subtracting the CT for the physician-taken sample from the CT for the self-taken sample.
TABLE 7 Comparison of genotype-speciﬁc signal strengths,a measured by the Onclarity assay, on self-taken samples and physician-taken
follow-up samplesb
HPV genotype
Median (IQR) CT for samples with the following resultsc:
Brush positive, physician negative (n  165) Brush positive, physician positive (n  339)
Self-taken samples Physician-taken samples Self-taken samples Physician-taken samples
HPV16 32.47 (30.27–33.29) Negative 26.47 (23.49–29.99) 25.34 (22.49–30.19)
HPV18 30.57 (28.45–31.88) Negative 27.46 (23.85–29.81) 27.90 (23.95–29.81)
HPV31 30.66 (27.67–31.94) Negative 25.85 (22.65–30.30) 26.65 (23.18–29.65)
HPV33/58 28.11 (26.93–31.23) Negative 28.26 (24.74–30.61) 26.76 (24.04–29.92)
HPV35/39/68 30.65 (25.40–31.72) Negative 26.44 (24.87–30.46) 27.14 (24.71–30.70)
HPV45 29.55 (27.59–32.90) Negative 27.33 (23.66–31.56) 29.88 (25.69–31.88)
HPV51 30.45 (26.76–32.84) Negative 25.75 (22.79–30.18) 28.45 (24.96–32.84)
HPV52 30.00 (28.96–31.34) Negative 26.04 (22.02–28.73) 26.31 (18.97–30.81)
HPV56/59/66 30.75 (28.81–32.66) Negative 26.04 (21.73–29.52) 27.21 (23.59–30.44)
aExpressed as the cycle threshold (CT). The cutoff was a CT value of 34.2.
bIn total, of the 532 women with HPV infections detected by the Onclarity assay on the self-taken sample who had follow-up physician testing, 504 (95%) had a valid
Onclarity test result on the physician sample.
cIQR, interquartile range. “Brush positive,” HPV-positive test results for self-taken samples; “physician negative,” HPV-negative test results for physician-taken follow-up
samples.
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resuspend the self-sampling brush heads prior to analysis, has not been used for
self-sampling previously, although it has been used extensively on physician-taken
screening samples (18). The CLART assay is a well-described assay with good perfor-
mance compared to the HC2 assay on both SurePath (19) and ThinPrep (20) samples
and has been used for self-sampling in our laboratory previously (21).
Clinical implications and comparison with other studies. This is one of the ﬁrst
studies comparing different HPV assays in terms of their ability to detect HR-HPV in
self-taken samples. Besides, this is an unsupervised self-sampling setting, which is the
most relevant setting for a routine rollout of this service to screening nonattenders.
In line with previously published experience on physician-taken samples (14, 22), we
found the positive agreement between the Onclarity and CLART assays to be just above
60%. This is comparable to the detection of HPV in routinely screened women, where
pairwise agreement in a screening population reached 58% for the CLART and cobas
assays (14). The agreement with the HC2 assay in this self-sampling population was
below 40%, and the detected HPV prevalence was also lower on the HC2 assay than on
the other two assays. Whereas the majority of European self-sampling studies in
well-screened populations used only the HC2 assay for the detection of HPV infections
(2, 4–8, 10), Enerly and colleagues (21) used the HC2 and CLART assays to investigate
HPV prevalence among 169 women who returned a self-taken sample for HPV detec-
tion. In this small study, with the HPV analyses performed in our laboratory, the positive
agreement for the assays was still only 50%. The disagreement is mainly technology
driven (14), but our results underline the need for validation criteria for HPV testing on
self-taken samples to facilitate a minimum of quality assurance.
For screening purposes, the relevant endpoint is histological conﬁrmation of pre-
cancerous high-grade cervical lesions especially; this is beyond the scope of the current
analysis and will be reported in detail separately.
One-third of the women found HPV positive on the self-taken sample were found
HPV negative on the follow-up physician-taken sample. This discrepancy is highly
interesting and relevant to the future implementation of self-sampling. One explana-
tion for this observation could be spontaneous HPV clearance, yet the same decrease
in HPV detection in the physician-taken sample was also seen in women who came for
follow-up within 1 month after returning the self-taken sample. Alternatively, some
women may have inadvertently sampled the vaginal canal, whereas the physicians are
taught to visualize the cervix prior to taking the screening sample. Finally, self-taken
samples were preprocessed in 3 ml CBD, whereas the physician-taken samples were
suspended in 10 ml SurePath. The higher concentration of biological material per
volume unit in a processed self-taken sample may lead to higher signal strengths (i.e.,
lower CT values) for real-time PCR and a higher proportion of samples above the cutoff
for HPV positivity. The CT values on positive self-taken samples of women whose
physician-taken samples were also HPV positive tended to be lower than those for
women whose physician-taken samples were HPV negative. Finally, stronger signals
TABLE 8Median signal strengtha on samples with HPV infections detected by one assay,
two assays, or three assaysb
Assay(s) by which samples were found
HPV positive No. of samples Median (IQR) CT value
One assay (Onclarity) 45 31.42 (29.80–33.28)
Two assays
Onclarity and CLART 45 30.05 (28.58–31.72)
Onclarity and HC2 9 25.45 (20.22–25.89)
All three assays (Onclarity, CLART, and HC2) 44 23.47 (21.50–24.91)
aCT value on the genotype-speciﬁc well with the strongest signal.
bFor 964 samples, all three assays (Onclarity, CLART, and HC2) gave valid results. In total, 166 samples
(17.2%) were HPV positive on at least one of the assays (Fig. 1). Of these, 143 (86.1%) were positive by
Onclarity, with CT values available for reporting.
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were found when all three assays conﬁrmed the HPV-positive test result than when
only one assay detected the infection. In line with our research on routinely screened
women from the Horizon study, this could also suggest that women whose HPV
infections had higher signal strengths may have been more likely to harbor high-grade
CIN (16). Nevertheless, this ﬁnding remains to be conﬁrmed for women undergoing
self-sampling.
Conclusion. Cervical cancer screening of nonattenders who participated in self-
sampling yielded an overall HPV prevalence of 16%, detected by any of the three HPV
assays used, which was somewhat lower than the prevalence detected among women
attending routine screening in the same screening laboratory. Self-sampling women,
however, had a higher proportion of cytological abnormalities upon follow-up. As in
routine screening, self-taken samples showed substantial discordance between assays
detecting HPV infections.
MATERIALS AND METHODS
Study design. In Denmark, women are invited for screening every 3 years (at the ages of 23 to 49
years) or every 5 years (at the ages of 50 to 65 years). The design of the CSi study has been explained
elsewhere (13). Brieﬂy, 23,632 nonattenders (deﬁned as having had no screening for 4 years [at ages
27 to 49] or 6 years [at ages 50 to 65]) from the Capital Region were invited to order a self-sampling
brush (Evalyn; Rovers, Oss, the Netherlands). In total, 4,824 (20%) women returned the self-taken sample.
Each brush was preprocessed and was aliquoted into four split samples (Fig. 2). For clinical management
FIG 2 Flow chart of the study design: HPV prevalence and follow-up cytology. (a) A total of 23,632 nonattenders from the Capital
Region were invited to be screened via self-sampling; of these, 4,824 (20%) accepted the offer and returned a self-sampling test. (b)
Self-taken samples were aliquoted into four split samples. The ﬁrst three aliquots were for HPV testing, and the fourth (not shown)
served as backup material and constituted a biobank. (c) All women with detected HPV infections were recommended to see their
GP for a cytology sample. Compliance to follow-up was 83.3% (641/769). (d) By mistake, 35 of the 641 (5.3%) follow-up samples were
not tested for HPV, but they all underwent cytology evaluation.
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within the study, a woman was considered HPV positive and recommended to undergo physician-
administered sampling if any of the three assays detected high-risk HPV (HR-HPV). Women were notiﬁed
of their results by letter, and the result was also sent to the general practitioner (GP) if consent was given
by the woman. The subsequent cytology follow-up samples were cotested for HPV and used for triage
to colposcopy. Women who were normal by cytology, regardless of the HPV test result, were recom-
mended for cytology and HPV cotesting after 12 months. Women who had ASCUS, regardless of the
HPV test result, were referred directly to colposcopy, which was also the case for women who had ASCUS
and were HPV positive. Women who were HPV negative but had ASCUS were recommended to have a
cytology retest after 6 months. The cytotechnician was not blinded to the woman’s HPV status. Women
with no HPV infections detected in their self-taken sample were recommended to participate in the next
round of routine screening.
The Horizon study was undertaken in the same screening laboratory in 2011 (14–16, 23–28), and from
this study, we included 3,347 women (27 to 65 years old) undergoing primary screening. Their
physician-taken SurePath samples were tested by the HC2, CLART, Aptima (Hologic, San Diego, CA, USA),
and cobas (Roche, Rotkreuz, Switzerland) assays. Concurrent cytological diagnoses were known for all
samples, and the cytotechnician was blinded to the HPV test results.
Preprocessing of self-sampling brushes. All returned brushes were preprocessed and were ana-
lyzed for HR-HPV. Brush heads were removed from the holders and were placed in empty 5-ml Eppendorf
tubes (see Text S1 in the supplemental material). Three milliliters of BD’s Cervical Brush Diluent (CBD) was
added. Brush heads were removed after 15 min, and samples were vortexed to achieve homogeneous
mixtures. Each sample was aliquoted into four empty tubes using the following schedule: 450 l was
transferred to an Eppendorf tube for DNA extraction and CLART analysis, 1,000 l to a tube for Onclarity
testing, and 500 l to a tube for HC2 analysis (the ﬁrst 1,008 brushes), while all residual material was
stored at 20°C for backup.
HPV DNA testing. For the CLART assay, two 200-l aliquots were transferred directly to a MagNA
Pure 96 system (Roche Diagnostics, Mannheim, Germany) for DNA puriﬁcation. The two 100-l puriﬁed
DNA outputs were then pooled. The assay provided full genotyping of 35 HPV types, without quanti-
tative measurement of signal strengths. For clinical management, HR-HPV types were deﬁned as HPV16,
-18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68, corresponding to the latest classiﬁcation of
genotypes as carcinogenic (group 1) or probably carcinogenic (group 2A) by the International Agency for
Research on Cancer (IARC) (29). Low-risk types were deﬁned as HPV6, -11, -26, -40, -42, -43, -44, -53, -54,
-61, -62, -66, -70, -71, -72, -73, -81, -82, -83, -84, -85, and -89, corresponding to the IARC deﬁnition as
possibly carcinogenic (group 2B) or low-risk (not classiﬁable as carcinogenic [group 3]) genotypes.
For the Onclarity assay, the 1,000-l aliquot was prewarmed for cell lysis. The sample was loaded into
the Viper Lt real-time PCR system (BD, Sparks, MD, USA). The Onclarity assay detects six HR-HPV
genotypes individually (HPV16, -18, -31, -45, -51, and -52), whereas another seven HR-HPV genotypes and
one low-risk HPV genotype are detected in three combinations (HPV33/58, HPV35/39/68, and HPV56/
59/66). The standard cycle threshold (CT) cutoff for HPV positivity is 34.2.
For the HC2 assay, DNA denaturation was performed manually on the 500-l CBD medium aliquot
before testing. HPV testing was performed on the automated Rapid Capture system (Qiagen, Gaithers-
burg, MD, USA), and the results were read automatically on a luminometer. The threshold for positive test
results was 1 relative light unit (RLU)/cutoff (CO). Due to budgetary restrictions, HPV testing by the HC2
assay was completed only on the ﬁrst 1,008 consecutive self-samples.
Data sources. Women’s screening histories since January 2000 were retrieved from the nationwide
Pathology Database (Patobank), which has been virtually complete for the entire country since the
mid-2000s.
The invitations for self-sampling were sent between May 2014 and April 2015. For the current
analysis, we retrieved the screening activities until November 2015, which allowed for delays in returning
the brush (13), the laboratory testing and reporting, and the cytology follow-up.
Women were categorized as “intermittently screened” if they had a cytology sample within the last
10 years before the self-sampling invitation and as “long-term unscreened” if they had no sample for10
years. The analyses using this categorization were restricted to women34 years old, i.e., those who had
been eligible for screening for 10 years.
Statistical analyses. Due to hardware failure and technical issues with the Viper Lt system, some of
the samples were stored at20°C before testing with the Onclarity assay. No signiﬁcant differences were
seen when HPV prevalences determined for frozen and fresh samples were compared, including a
comparison of the respective CT values and adjustment for age (data not shown). Hence, we included all
test results in the analyses.
As in the Horizon study (14), positive agreement between assays was calculated as the proportion of
samples testing positive on any assay that were conﬁrmed by all assays compared.
For the comparison of positive HPV test results in self-taken samples and physician-taken follow-up
samples, we calculated medians and interquartile ranges (IQR) for the signal strengths (CT values) of the
Onclarity assay. The CT medians were stratiﬁed according to the median follow-up time (27 days) for
women who went for follow-up.
The 95% conﬁdence intervals (CIs) for proportions and for prevalence agreement were calculated on
the assumption that they were binomially distributed, whereas the 95% CIs for mean differences in CT
values were calculated by taking into account that the observed differences were normally distributed.
Stata SE 13.1 and Microsoft Excel 2010 were used for data analyses.
Ethical approval. The CSi was a time-limited pilot implementation initiative mandated by the Danish
Health Authority. The Horizon study was undertaken as a quality development study in accordance with
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the Committee Act under The National Committee on Health Research Ethics (2011 §14, part 3). In both
cases, therefore, formal ethical approval was not required. Linkage to the Patobank was approved by the
Danish Data Protection Agency under notiﬁcation numbers AHH-2015-084-04139 and AHH-2015-080-
04109 for the CSi and Horizon studies, respectively.
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